<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">IRINOTECAN HYDROCHLORIDE</span><br/>(eye-ri-no'te-can)<br/><span class="topboxtradename">Camptosar<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">camptothecin</span><br/><b>Prototype: </b>Topotecan<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Irinotecan is a camptothecin analog that displays antitumor activity by inhibiting the intranuclear enzyme topoisomerase I.
         Thus, it is a strong inhibitor of DNA and RNA synthesis. Topoisomerase I is an essential intranuclear enzyme that relaxes
         the supercoiled DNA, thus enabling replication and transcription to take place.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>By inhibiting topoisomerase I, irinotecan and its active metabolite SN-38 cause double-stranded DNA damage during the synthesis
         (S) phase of DNA. This inhibits both DNA and RNA synthesis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Metastatic carcinoma of colon or rectum.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Previous hypersensitivity to irinotecan, topotecan, or other camptothecin analogs; acute infection, diarrhea, pregnancy (category
         D), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Gastrointestinal disorders, myelosuppression, renal or hepatic function impairment, history of bleeding disorders, previous
         cyotoxic or radiation therapy. Safety and effectiveness in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Metastatic Carcinoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 125 mg/m<sup>2</sup> once weekly for 4 wk, then a 2-wk rest  period (future courses may be adjusted to range from 50 to 150 mg/m<sup>2</sup> depending on tolerance; see complete prescribing information for specific dosage adjustment recommendations based on toxic
               effects)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Administer only after premedication (at least 30 min prior) with an antiemetic.</li>
<li>Wash immediately with soap and water if skin contacts drug during preparation.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span>  Dilute the ordered dose in enough D5W (preferred) or NS to yield a concentration of 0.121.1 mg/mL. Typical amount of
                  diluent used is 500 mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span> Infuse over 90 min. Closely monitor IV site; if extravasation occurs, immediately flush with sterile water and apply ice.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store undiluted at 15°30° C (59°86° F) and protect from light. Use reconstituted solutions
            within 24 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Asthenia, fever, pain,</span> chills, edema, abdominal enlargement, back pain. <span class="typehead">CNS:</span> Headache, <span class="speceff-common">insomnia, dizziness</span>. <span class="typehead">CV:</span> Vasodilation/flushing. <span class="typehead">GI:</span> <span class="speceff-common">Diarrhea (early and late onset), dehydration, nausea, vomiting, anorexia, weight loss, constipation, abdominal cramping and
         pain,</span> flatulence, stomatitis, dyspepsia, increased alkaline phosphatase and AST. <span class="typehead">Hematologic:</span> <span class="speceff-both">Leukopenia, neutropenia</span>, <span class="speceff-common">anemia.</span> <span class="typehead">Respiratory:</span> <span class="speceff-common">Dyspnea,</span> cough, rhinitis. <span class="typehead">Skin:</span> <span class="speceff-common">Alopecia,</span> sweating, rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">anticoagulants</span>, <span class="classification">antiplatelet agents</span>, <span class="classification">nsaids</span> may increase risk of bleeding; <b>carbamazepine,</b> <b>phenytoin,</b> <b>phenobarbital</b> may decrease irinotecan levels. <span class="typehead">Herbal:</span> <b>St. John's wort</b> may decrease irinotecan levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span>  1 h. <span class="typehead">Distribution:</span> Irinotecan is 30% bound to plasma proteins; active metabolite SN-38 is 95% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by carboxylesterase enzyme to active metabolite SN-38. <span class="typehead">Elimination:</span> 10 h for SN-38; approximately 20% excreted in urine. <span class="typehead">Half-Life:</span> 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor WBC with differential, Hgb, and platelet count before each dose; monitor closely coagulation parameters
            especially with concurrent use of other drugs which affect these parameters.
         </li>
<li>Lab tests: Monitor fluid and electrolyte balance closely during and after periods of diarrhea. Monitor liver and renal function
            tests and blood glucose periodically.
         </li>
<li>Monitor for acute GI distress, especially early diarrhea (within 24 h of infusion), which may be preceded by diaphoresis and
            cramping, and late diarrhea (&gt;24 h after infusion).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn about common adverse effects and measures to control or minimize when possible.</li>
<li>Notify physician immediately when you experience diarrhea, vomiting, and S&amp;S of infection. Diarrhea requires prompt treatment
            to prevent serious fluid and electrolyte imbalances.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>